BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues

Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 GuidanceFull-year 2023 Top-line and Bot...

Related Keywords

France ,Germany ,Brazil ,Italy ,Canada ,Japan ,United States ,German ,Traci Mccarty ,Jean Jacques Bienaim ,Marni Kottle ,National Association Of Statuary Health Insurance Funds ,International Number ,Company As ,Company Annual ,Biomarin Genzyme ,Prnewswire Biomarin Pharmaceutical Inc ,European Commission ,Exchange Commission ,Drug Administration ,Biomarin Pharmaceutical Inc ,Replay International Number ,Nasdaq ,Development Expense ,Development Portfolio ,Rapid Uptake ,Brazil Resulting ,Increased Full Year ,Bottom Line Financial Guidance Reaffirmed ,Net Product Revenue Guidance Adjusted ,Growing Pipeline ,Severe Hemophilia ,Getting Tested ,Preparations Underway Ahead ,Drug User Fee Act ,Target Action ,Months Ended March ,Product Revenues ,Rare Pediatric Disease Priority Review Voucher ,Marin Pharmaceutical ,Chief Executive Officer ,Outcomes Based Agreements ,Total Revenues ,Product Approvals ,National Association ,Statuary Health Insurance Funds ,Named Patient ,Biologics License Application ,Major Amendment ,Product Life Cycle Expansion Opportunities ,New York City ,Hereditary Angioedema ,Duchenne Muscular Dystrophy ,Investigational New Drug ,Year Financial Guidance ,Canada Dial In Number ,Dial In Number ,International Dial In Number ,Biomarin Pharmaceutical ,Net Product Revenues ,Enzyme Product Revenues ,Gross Profit ,Administrative Expense ,Annual Report ,Nonqualified Deferred Compensation Plan ,Consolidated Financial Statements ,Net Income ,Average Dilutive Shares Outstanding ,Year Ended December ,